Scholarlink

<p>Cardiovascular conditions account for millions of deaths globally. Myocardial infarction (MI) remains the foremost cause of cardiovascular death. Post-MI pathology can activate a diverse type of programmed cell death (PCD), which aggravates cardiac dysfunction and causes post-ischemic heart failure. Although various PCD inhibitors have shown potential efficacy against several cardiac complications, their roles in preventing or reducing myocardial loss and dysfunction in post-MI pathology have never been clarified. A rat model of MI was used in this study and post-MI rats were randomly assigned into 5 subgroups (<i>n</i> = 7/group): (1) vehicle (3%V/V DMSO), (2) enalapril (10&#xa0;mg/kg), (3) zVAD-FMK (1&#xa0;mg/kg), (4) Necrostatin-1 (1.65&#xa0;mg/kg), or (5) Ferrostatin-1 (2&#xa0;mg/kg). All treatments were given for 32 days via intraperitoneal injection. A control group of sham-operated rats underwent thoracotomy without left anterior descending (LAD) artery occlusion (<i>n</i> = 7). After 32 days of treatment, echocardiography and ventricular pressure-volume (P-V) loop studies, mitochondrial function, histopathological studies, and molecular analysis were carried out. Treatment with zVAD-FMK, Necrostatin-1, and Ferrostatin-1 mitigated pathological cardiac remodeling, reduced apoptosis and necroptosis-mediated myocardial injury, alleviated mitochondrial dysfunction, and improved cardiac function in post-MI rats. These findings indicated that inhibition of apoptosis and necroptosis could be novel strategies for treatment in post-MI conditions.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Pharmacological inhibition of apoptosis, necroptosis, and ferroptosis confers effective cardioprotection in post-myocardial infarction in rats

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年8月24日

查看全文
  • Chanon Piamsiri,
  • Chayodom Maneechote,
  • Kewarin Jinawong,
  • Busarin Arunsak,
  • Titikorn Chunchai,
  • Siriporn C. Chattipakorn,
  • Nipon Chattipakorn

摘要

Cardiovascular conditions account for millions of deaths globally. Myocardial infarction (MI) remains the foremost cause of cardiovascular death. Post-MI pathology can activate a diverse type of programmed cell death (PCD), which aggravates cardiac dysfunction and causes post-ischemic heart failure. Although various PCD inhibitors have shown potential efficacy against several cardiac complications, their roles in preventing or reducing myocardial loss and dysfunction in post-MI pathology have never been clarified. A rat model of MI was used in this study and post-MI rats were randomly assigned into 5 subgroups (n = 7/group): (1) vehicle (3%V/V DMSO), (2) enalapril (10 mg/kg), (3) zVAD-FMK (1 mg/kg), (4) Necrostatin-1 (1.65 mg/kg), or (5) Ferrostatin-1 (2 mg/kg). All treatments were given for 32 days via intraperitoneal injection. A control group of sham-operated rats underwent thoracotomy without left anterior descending (LAD) artery occlusion (n = 7). After 32 days of treatment, echocardiography and ventricular pressure-volume (P-V) loop studies, mitochondrial function, histopathological studies, and molecular analysis were carried out. Treatment with zVAD-FMK, Necrostatin-1, and Ferrostatin-1 mitigated pathological cardiac remodeling, reduced apoptosis and necroptosis-mediated myocardial injury, alleviated mitochondrial dysfunction, and improved cardiac function in post-MI rats. These findings indicated that inhibition of apoptosis and necroptosis could be novel strategies for treatment in post-MI conditions.